Source::Xinhuanet
XINHUA/RSS
India's vaccine maker Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin has shown 77.8 percent efficacy in phase 3 clinical trials. The data, however, is yet to be peer-reviewed.
Covaxin is a whole virus inactivated vaccine against SARS-CoV2, developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) in Pune.
The Phase 3 clinical trial was an event-driven analysis of 130 symptomatic COVID-19 cases, reported at least two weeks after the 2nd dose, conducted at 25 sites across India.
"Efficacy analysis demonstrates Covaxin to be 77.8 percent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group," the vaccine maker said.
The company said the vaccine offers "65.2 percent protection" against the rapidly emerging Delta variant. It was also found to be "93.4 percent effective" against severe symptomatic COVID-19, the company added. Covaxin is one of the three vaccines which are currently being used in India.
ALSO READ
